FY2024 Q3 Earnings Announcement
Committed to Growth & Shareholder Returns

from the beginning

FY2024 Q3 Earnings Announcement

Important Notice

• Opening Remarks

• Presentation

FY2024 Q3 YTD Results Driven by Growth & Launch Products, Continued VYVANSE Demand, and OPEX Efficiencies

Strong Momentum of Growth & Launch Products +14.6% at CER

FY2024 Q3 YTD Revenue: Growth & Launch Products More Than Offset Loss of Exclusivity Impact

FY2024 Q3 YTD Core Operating Profit: Growth & Launch Products More Than Offset LOE Impact, with OPEX Benefitting from Efficiency Program

FY2024 Q3 YTD Reported Operating Profit: Increase Reflects Growth in Core Operating Profit and Lower Impairment Compared to Prior Year

Raising Full-Year Outlook: Expecting Revenue, Core O.P. & Margin Growth and Announcing Share Buyback up to JPY 100.0B

FY2024 Forecast Upgrade Driven by Product Momentum, Slower Than Anticipated VYVANSE Generic Erosion in the U.S., & OPEX Savings

Q&A SESSION

• Q&A SESSION1

• Q&A SESSION2

• Q&A SESSION3

• Q&A SESSION4

• Q&A SESSION5

• Q&A SESSION6

• Q&A SESSION7

• Q&A SESSION8

• Q&A SESSION9

• Q&A SESSION10

• Q&A SESSION11

APPENDIX

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@